- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Low-dose hydroxyurea therapy may prevent stroke in children with sickle-cell anemia: Lancet
Kano, Nigeria: A new study found that as compared to low-dose hydroxyurea therapy, moderate-dose hydroxyurea therapy showed no change in stroke incidence rate in children with sickle cell anemia. Secondary analyses, however, show that the moderate-dose group may have a reduced incidence rate of all-cause hospitalizations.
The findings, published in The Lancet Haematology, provide an evidence-based guideline for the use of low-dose hydroxyurea therapy for primary stroke prevention in children with sickle cell anemia.
Standard care for primary stroke prevention in children with sickle cell anemia and abnormal transcranial Doppler velocities results in a 92% relative risk reduction of strokes in high-income countries but warrant initial monthly blood transfusion. In Africa, regular blood transfusion is not feasible for most children.
Given the above background, Shehu U Abdullahi and the team conducted the study with the objective to test in children with aberrant transcranial Doppler velocities, starting with moderate-dose hydroxyurea rather than a low-dose reduces the risk of stroke.
SPRING is a phase 3 study of children aged 5–12 years with sickle cell anemia and aberrant transcranial Doppler velocities that is being done at three teaching hospitals in Nigeria. We employed a permuted block allocation approach with four block sizes, stratified by sex and site, for randomization. Except for the pharmacists and statisticians, the allocation was kept secret. Participants were randomly randomized to receive either low-dose (10 mg/kg per day) or moderate-dose (20 mg/kg per day) oral hydroxyurea once daily, with monthly clinical evaluation and laboratory monitoring. The primary outcome was a centrally assessed first stroke or transient ischemic attack. The secondary outcome was hospitalization for any reason. For data analysis, we employed the intention-to-treat population.
The results of this work stated as follow:
1. Between August 2, 2016, and June 14, 2018, 220 people were assigned at random and tracked for a median of 24 years.
2. All of the participants were Nigerians from the following ethnic groups: 179 persons (82%) identified as Hausa, 25 (11%) as Fulani, and 16 (7%) as another ethnicity.
3. Three (3%) of 109 participants in the low-dose hydroxyurea group had strokes, with an incidence rate of 119 per 100 person-years, while five (5%) of 111 in the moderate-dose hydroxyurea group had strokes, with an incidence rate of 192 per 100 person-years.
4. The incidence rate ratio of hospitalization for any cause was 171, with the low-dose group having greater incidence rates per 100 person-years than the moderate-dose group. No participant's hydroxyurea medication was discontinued due to myelosuppression.
In conclusion, these findings give an evidence-based recommendation for low-dose hydroxyurea treatment in children with sickle cell anemia who are at risk of stroke.
Reference:
Abdullahi, S. U., Jibir, B. W., Bello-Manga, H., Gambo, S., Inuwa, H., Tijjani, A. G., Idris, N., Galadanci, A., Hikima, M. S., Galadanci, N., Borodo, A., Tabari, A. M., Haliru, L., Suleiman, A., Ibrahim, J., Greene, B. C., Ghafuri, D. L., Rodeghier, M., Slaughter, J. C., … DeBaun, M. R. (2022). Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. In The Lancet Haematology (Vol. 9, Issue 1, pp. e26–e37). Elsevier BV. https://doi.org/10.1016/s2352-3026(21)00368-9
Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751